Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARGIN-II breast-conserving surgery fluorescence imaging study
2018-003614-40Phase 2Completed
- Sponsor
- Bracco Group
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in breast cancer, sponsored by Bracco Group. Primary endpoints: Positive tumor margins after standard of care and molecular fluorescence-guided surgery and Surgical re-excision rate within 30 days after breast-conserving surgery. Started Nov 2018; status: completed.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2018-003614-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003614-40.